Court of Justice 27 March 2025, C-2/24 P (Teva Pharmaceutical Industries Ltd and Cephalon Inc. v European Commission.)

Also known as

The Advocate General's Opinion addresses the appeal by Teva Pharmaceutical Industries Ltd and Cephalon Inc. against the General Court's dismissal of their challenge to the European Commission's decision, which found their settlement agreement regarding modafinil to be a restriction of competition under Article 101 TFEU and Article 53 of the EEA Agreement. The Opinion scrutinizes the legal characterization of the settlement agreement as a restriction by object and effect, emphasizing the need for a nuanced assessment of whether such agreements inherently harm competition or if they can be justified by legitimate business considerations. Ultimately, the Advocate General suggests that the criteria for evaluating these agreements should be clarified to ensure a balanced approach to competition law in the pharmaceutical sector.AI